NASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis → Who are Nvidia’s Silent Partners? (From Weiss Ratings) (Ad) Free CNTA Stock Alerts $8.36 -0.39 (-4.46%) (As of 11:51 AM ET) Add Compare Share Share Today's Range$8.25▼$8.6450-Day Range$8.60▼$12.2052-Week Range$3.96▼$12.45Volume103,189 shsAverage Volume330,589 shsMarket Capitalization$840.01 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Centessa Pharmaceuticals alerts: Email Address Centessa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside19.5% Upside$10.00 Price TargetShort InterestBearish2.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 5 Articles This WeekInsider TradingSelling Shares$607,781 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.76) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 starsMedical Sector642nd out of 920 stocksPharmaceutical Preparations Industry299th out of 427 stocks 2.4 Analyst's Opinion Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCentessa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Centessa Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.99% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently increased by 39.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTA. Previous Next 3.3 News and Social Media Coverage News SentimentCentessa Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Centessa Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for CNTA on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $607,781.00 in company stock.Percentage Held by Insiders11.59% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Centessa Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.76) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Centessa Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.Read More CNTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTA Stock News HeadlinesMay 21 at 8:45 AM | globenewswire.comCentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 21 at 6:18 AM | americanbankingnews.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Average Recommendation of "Moderate Buy" by AnalystsMay 17, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Centessa Pharmaceuticals plc Increased by Leerink Partnrs (NASDAQ:CNTA)May 14, 2024 | markets.businessinsider.comBuy Rating on Centessa Pharmaceuticals Based on Strong Pipeline and Financial HealthMay 13, 2024 | investorplace.comCNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024May 13, 2024 | finance.yahoo.comCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024May 13, 2024 | globenewswire.comCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024April 24, 2024 | seekingalpha.comCentessa: Hemophilia B Data Readout In 2024 Is Major Turning PointApril 24, 2024 | nasdaq.comCentessa Pharma Prices Public Offering Of About 10.81 Mln ADSs At $9.25/ADSApril 23, 2024 | globenewswire.comCentessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesApril 23, 2024 | globenewswire.comCentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesApril 22, 2024 | baystreet.caCentessa Gains on New Product NewsApril 22, 2024 | globenewswire.comCentessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024April 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial ResultsMarch 29, 2024 | msn.comCNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023March 28, 2024 | finanznachrichten.deCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023March 28, 2024 | finance.yahoo.comCentessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 ResultsMarch 28, 2024 | globenewswire.comCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023March 27, 2024 | finance.yahoo.comCentessa Pharmaceuticals PLC Chief People Officer Sells Company SharesMarch 26, 2024 | finance.yahoo.com7 Biotech Stocks Ready to Ride the Sector’s ResurgenceMarch 20, 2024 | wsj.comCentessa Pharmaceuticals PLC ADRMarch 19, 2024 | investing.comCentessa Pharmaceuticals PLC ADR (CNTA)March 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comCNTA Apr 2024 7.500 putMarch 16, 2024 | finance.yahoo.comCNTA Apr 2024 5.000 callSee More Headlines Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/23/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNTA CUSIPN/A CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$15.00 Low Stock Price Target$5.00 Potential Upside/Downside+17.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,090,000.00 Net MarginsN/A Pretax Margin-2,388.28% Return on Equity-56.07% Return on Assets-37.96% Debt Debt-to-Equity Ratio0.36 Current Ratio10.37 Quick Ratio10.37 Sales & Book Value Annual Sales$6.85 million Price / Sales125.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book4.00Miscellaneous Outstanding Shares100,480,000Free Float88,836,000Market Cap$859.10 million OptionableOptionable Beta1.44 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Saurabh Saha M.D. (Age 48)Ph.D., CEO & Director Comp: $957.67kDr. Gregory M. Weinhoff M.B.A. (Age 53)M.D., Principal Accounting Officer & CFO Comp: $655kDr. David M. Chao Ph.D. (Age 56)Chief Administrative Officer Comp: $655kMs. Tia L. Bush (Age 53)Chief Technology & Quality Officer Ms. Kristen K. Sheppard Esq.J.D., Senior Vice President of Investor Relations & Corporate CommunicationsMr. Iqbal J. Hussain L.L.B. (Age 43)General Counsel, Chief Compliance Officer & Corporate Secretary Ms. Karen M. Anderson (Age 56)Chief People Officer Dr. Antoine Yver M.D. (Age 66)M.Sc., Executive VP & Chairman of Development Comp: $449.58kDr. Harris L. Rotman Ph.D.Senior Vice President of Regulatory AffairsDr. Patrick Yue M.D.Senior VP of Clinical Development & Innovative MedicinesMore ExecutivesKey CompetitorsARS PharmaceuticalsNASDAQ:SPRYPliant TherapeuticsNASDAQ:PLRX89bioNASDAQ:ETNBABIVAX Société AnonymeNASDAQ:ABVXZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsArtal Group S.A.Bought 400,000 shares on 5/17/2024Ownership: 1.250%First Light Asset Management LLCBought 3,002,045 shares on 5/15/2024Ownership: 2.980%Price T Rowe Associates Inc. MDBought 418,615 shares on 5/15/2024Ownership: 2.936%Affinity Asset Advisors LLCBought 34,817 shares on 5/15/2024Ownership: 0.824%EntryPoint Capital LLCBought 9,636 shares on 5/14/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions CNTA Stock Analysis - Frequently Asked Questions Should I buy or sell Centessa Pharmaceuticals stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CNTA shares. View CNTA analyst ratings or view top-rated stocks. What is Centessa Pharmaceuticals' stock price target for 2024? 7 brokerages have issued 1 year price objectives for Centessa Pharmaceuticals' shares. Their CNTA share price targets range from $5.00 to $15.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts price targets for CNTA or view top-rated stocks among Wall Street analysts. How have CNTA shares performed in 2024? Centessa Pharmaceuticals' stock was trading at $7.96 at the beginning of 2024. Since then, CNTA shares have increased by 5.2% and is now trading at $8.37. View the best growth stocks for 2024 here. When is Centessa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CNTA earnings forecast. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals plc (NASDAQ:CNTA) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.06. The company had revenue of $6.85 million for the quarter. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Centessa Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (2.98%), Price T Rowe Associates Inc. MD (2.94%), Artal Group S.A. (1.25%), Affinity Asset Advisors LLC (0.82%), Platinum Investment Management Ltd. (0.48%) and Acadian Asset Management LLC (0.03%). Insiders that own company stock include (Bermuda) Ltd Gap, Aaron Kantoff, Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Karen M Anderson, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman and Tia L Bush. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTA) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeU.S. Drone Company Receives DoD CertificationThe Tomorrow InvestorTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTruth about Trump you’ve never heardPorter & CompanyDividend-like income from non-dividend stocksUnstoppable ProsperityThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarAlex’s “Next Magnificent Seven” stocksThe Oxford ClubWhat is Nvidia’s New $1 Trillion Superproject?Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.